Evidence map›Paper›PMID 20046814›Full record

ArticleThe Journal of respiratory diseases2008

Bronchiectasis, part 2: Management.

Meeta Prasad, Gregory Tino

Open access · greenAbstract read
In one paragraph

Article in The Journal of respiratory diseases, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.5field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 4 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Meeta PrasadDivision of Pulmonary, Allergy, and Critical Ccare Medicine of the University of Pennsylvania Health System, Philadelphia. Dr. Prasad is a postgraduate fellow, and Dr. Tino is associate professor of medicine and chief, pulmonary clinical service, Hospital of the University of Pennsylvania.
Gregory Tino
Hospital of the University of Pennsylvania · US

Funding

Cardiology & pulmonary research training grantT32HL007891 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI Jason D Christie · 1998 to 2026
$12.0M
NHLBI NIH HHS T32 HL007891
6 · The paper itself

Abstract

Systemic antibiotics are the mainstay of the management of acute exacerbations of bronchiectasis. Antibiotic selection should include coverage for Streptococcus pneumoniae and Haemophilus influenzae; particular attention also should be paid to the presence of Staphylococcus aureus and Pseudomonas species. The duration of antibiotic therapy is not well-established, but most clinicians recommend a prolonged course, often longer than 3 weeks. There is some evidence that long-term low-dose macrolide therapy can reduce the incidence of acute exacerbations and decrease sputum production. There also may be a role for the use of inhaled antibiotics. Airway clearance strategies, such as chest percussion and postural drainage, are clearly useful in patients with cystic fibrosis and may be useful in other patients with bronchiectasis. Surgical resection can be considered if a patient has localized disease that is refractory to medical management or if he/she is unwilling to undergo long-term medical therapy.

Identifiers

PMID20046814
PMCPMC2799935
OpenAlexW115302054

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.